AbbVie/ News/ R&D/ Top stories AbbVie signs $225m ‘immunoneurology’ deal to tackle Alzheimer’s Marco Ricci AbbVie, Alector, Alzheimer's disease, immuno-neurology 0 Comment Partnership will use novel approach to treating Alzheimer’s. Share X AbbVie signs $225m ‘immunoneurology’ deal to tackle Alzheimer’s https://pharmaphorum.com/news/abbvie-immunoneurology-alzheimers/